One‐year clinical outcomes and multislice computed tomography angiographic results following implantation of the<scp>N</scp>eo<scp>V</scp>as bioresorbable sirolimus‐eluting scaffold in patients with single de novo coronary artery lesions

Wang, Xiaozeng; Zhang, Yaojun; Fu, Guosheng; Jing, Quanmin; Xu, Bo; Han, Yaling

doi:10.1002/ccd.27491

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, two recent meta-analyses [ 28 , 29 ] showed ABSORB bioresorbable coronary stents to be associated with increased risk of stent thrombosis and target lesion failure (target vessel myocardial infarction and lesion revascularisation), in comparison to cobalt-chromium everolimus-eluting metallic stents. Despite these results, improvements can be expected from newer scaffold designs with thinner struts (125 μm and less) [ 30 , 31 ], eluting drugs other than everolimus [ 32 ], dedicated implantation protocols [ 13 ], optimized lesion and patient selection, as well as modified antithrombotic therapy protocols [ 33 ]. In this context, feasibility of intrastent CT imaging makes the latter a valuable noninvasive tool for assessment of new BRS technologies.…”

Section: Discussionmentioning

confidence: 99%

Coronary bioresorbable stents: Non-invasive quantitative evaluation of intra- and juxta-stent plaque composition—A computed tomography longitudinal study

Zdanovich

Mansour²,

Stevens³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Purpose Coronary bioresorbable stents (BRS) do not produce blooming artifacts on computed tomography (CT), in contrast to metallic stents, as they are made of a bioresorbable polymer and are radiolucent. They allow to evaluate the coronary plaque beneath. The low-attenuation plaque (LAP) suggests plaque vulnerability and is CT assessable. The aim of our study was to show the possibility of a non-invasive CT evaluation of the volume and the LAP composition of the intra- and juxta-stent plaque. Methodology In our prospective longitudinal study, we recruited 27 consecutive patients (35 BRS stents total; mean age 60 +/- 9 years) with bioresorbable stents for a 256-slice ECG-synchronized CT evaluation at 1- and 12-months post stent implantation. Total plaque volume (mm3), absolute and relative (%) LAP volume per block in the pre- intra- and post-stent zones were analyzed; comparison 1- and 12-months post-implantation of BRS. Changes in the previously mentioned variables were assessed by the mixed effects models with and without spline, which also accounted for the correlation between repeated measurements. Results Our block or spline model analysis has shown no significant difference in plaque or absolute LAP volumes in pre- intra- and post-stent zones between 1 and 12 months. Interestingly, % LAP volume increases near-significantly in the distal block of the intrastent at 12-mo follow-up (from 23.38 ± 1.80% to 26.90 ± 2.22% (increase of 15%), p = 0.052). Conclusion Our study demonstrates the feasibility of the repeated non-invasive quantitative analysis of the intrastent coronary plaque and of the in-stent lumen by CT scan.

show abstract

Section: Discussionmentioning

confidence: 99%

Coronary bioresorbable stents: Non-invasive quantitative evaluation of intra- and juxta-stent plaque composition—A computed tomography longitudinal study

Zdanovich

Mansour²,

Stevens³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…A meta-analysis published on Lancet in 2017 showed that coronary artery diameter <2.25 mm and female sex were independent risk factors for in-stent thrombosis. [16] In 2018, Wang et al [17] conducted an observation of 31 cases implanted with NeoVas scaffold in PCI over a 1-year period and reported no cardiac death or in-stent thrombosis, except for 1 case who suffered recurrent ischemic events. This finding supports the implantation of NeoVas scaffold as demonstrated in our study.…”

Section: Discussionmentioning

confidence: 99%

Antiphospholipid syndrome combined with acute coronary syndrome

Yuan

Wang²,

Liu³

2018

Medicine

View full text Add to dashboard Cite

Rationale:Antiphospholipid syndrome (APS) combined with acute coronary syndrome (ACS) is rarely reported.Patient concerns:One male patient with APS was admitted to our hospital, who had recent unstable angina (UA).Diagnosis:The preliminary diagnosis of ACS and UA (BraunwaldiB) was then made.Interventions:This patient received secondary preventative therapy for coronary heart disease (CHD) in combination with percutaneous transluminal coronary angioplasty (PTCA) and implantation of NeoVas Bioresorbable Coronary Scaffold.Outcomes:The patient was followed up, without new UA episodes were observed at 6 months, 1 year, and 2 year after surgery, respectively.Lessons:It was thus concluded that percutaneous coronary intervention (PCI) is effective for APS patients and NeoVas scaffold implantation is presumed safe.

show abstract

“…The findings from First-in-man study, randomized clinical trial (RCT) and single-arm trial (NeoVas registry) have confirmed the efficacy and safety of the device for the treatment of patients with noncomplex coronary lesions. [11][12][13][14] The Chinese National Medical Products Administration (NMPA) had approved the NeoVas BRS to treat coronary artery disease on February 26, 2019.…”

Section: Introductionmentioning

confidence: 99%

Three‐year clinical outcomes of the novel sirolimus‐eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: A prospective patient‐level pooled analysis of NeoVas trials

Wang

Liu

et al. 2023

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

Objectives: We aimed to evaluate the long-term outcomes of the novel NeoVas sirolimus-eluting bioresorbable scaffold (BRS) for the treatment of de novo coronary artery disease.Background: The long-term safety and efficacy of the novel NeoVas BRS are still needed to be elucidated.Methods: A total of 1103 patients with de novo native coronary lesions for coronary stenting were enrolled. The primary endpoint of target lesion failure (TLF) was defined as a composite of cardiac death (CD), target vessel myocardial infarction (TV-MI), or ischemia-driven-target lesion revascularization (ID-TLR).

show abstract

One‐year clinical outcomes and multislice computed tomography angiographic results following implantation of theNeoVas bioresorbable sirolimus‐eluting scaffold in patients with single de novo coronary artery lesions

Cited by 6 publications

References 16 publications

Coronary bioresorbable stents: Non-invasive quantitative evaluation of intra- and juxta-stent plaque composition—A computed tomography longitudinal study

Coronary bioresorbable stents: Non-invasive quantitative evaluation of intra- and juxta-stent plaque composition—A computed tomography longitudinal study

Antiphospholipid syndrome combined with acute coronary syndrome

Three‐year clinical outcomes of the novel sirolimus‐eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: A prospective patient‐level pooled analysis of NeoVas trials

Contact Info

Product

Resources

About